Muzastotug is an Adagene Inc. program in late-line microsatellite stable colorectal cancer (MSS CRC) without liver metastases. Its next catalyst is a Readout in Q2 2027.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: Late-line microsatellite stable colorectal cancer (MSS CRC) without liver metastases. Sponsor: Adagene Inc. (ADAG). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for Muzastotug is a Readout in Q2 2027.
No FDA decision for Muzastotug is in our archive yet.
In our records Muzastotug is under review or in development for Late-line microsatellite stable colorectal cancer (MSS CRC) without liver metastases.
Adagene Inc. (ADAG).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.